



CORPORATE GOVERNANCE POLICIES AND DOCUMENTATION

1. Code of Ethics and Business Conduct
2. Insider Trading and Blackout Policy
3. Disclosure Policy

1. Code of Ethics and Business Conduct



MYDECINE INNOVATIONS GROUP INC.

Code of Ethics and Business Conduct

1.0 INTRODUCTION

Mydecine Innovations Group Inc. (“Mydecine”, the “Company”, “our” or “we”) is committed to a culture of honesty, integrity and accountability and to upholding ethical and legal standards vigorously as we pursue our financial objectives. We believe that maintaining the highest ethical standards of behaviour and lawful business conduct is critical to our success. We have adopted this Code of Ethics and Business Conduct (the “Code”) to outline the basic principles and policies that all our employees, officers, directors and representatives (our “team members”) are expected to follow everywhere and any time we do business. Consultants and other third parties working with us are also expected to act in accordance with the intent and spirit of this Code. For the purposes of this Code, Mydecine includes any subsidiaries of the Company as may exist from time to time.

2.0 APPLICATION AND MONITORING OF THIS CODE

2.1 Application of this Code

This Code applies to all directors, officers, employees and contractors of the Company and its subsidiaries (who are referred to collectively as “team members”).

Team members are expected to comply with all aspects of this Code and to support others in doing so. In the event that an individual violates this Code, Company policies and procedures, or any of the laws that govern the Company’s business, the Company will take immediate and appropriate action up to and including termination of employment, claims for reimbursement of losses or damages and reference to criminal authorities.

2.2 Monitoring Compliance and Waivers

The Board of Directors is responsible for monitoring compliance with this Code. A waiver of this Code will be granted only in exceptional circumstances. Any waivers from this Code that are granted for the benefit of the Company’s directors or executive officers shall be granted by the Board of Directors only. Any waiver for employees will be granted only upon approval by the Chief Executive Officer.

3.0 FOLLOW THIS CODE

3.1 We Treat Others Ethically

All team members are expected to deal fairly with suppliers, customers, stakeholders, and members of the communities in which we operate.

We will refrain from disparaging competitors and should not improperly seek competitor’s confidential information nor take improper or unlawful advantage of others in our business dealings. We will not take unfair advantage of anyone through manipulation, concealment,

abuse of privileged information, misrepresentation of material facts, or any other unfair-dealing practice.

3.2 We Promote a Positive Workplace

All team members deserve a workplace where they feel respected and valued. We respect cultural diversity and will not tolerate discrimination or harassment against any team member because of race, religion, color, sex, sexual orientation, age, national or ethnic origin, ancestry, marital or family status, or disability.

Management is especially committed to the promotion of a positive work environment and for taking care not to exert pressure or appear to exert pressure on subordinates that could cause them to engage in unethical behaviour.

3.3 We Work Safely and Protect Others and the Environment

We are committed to conducting all our operations in a manner that protects the health and safety of team members and all people in the communities where we operate.

We are all responsible for supporting the Company's commitment to environmental responsibility and for complying with environmental regulations.

We are committed to a drug-free, safe and healthy workplace and the use of illicit drugs, the inappropriate use of alcohol and the misuse of medications and other substances is prohibited.

3.4 We Obey the Law

We will comply with all laws, regulations and other legal requirements applicable to our business. Each team member will:

- a) adhere to the standards and restrictions imposed by the laws, rules, and regulations applicable to our business;
- b) avoid situations that could be perceived as improper or unethical or indicate a lack of compliance with the law;
- c) become aware of the laws, rules, and regulations that govern our work;
- d) recognize potential liabilities and seek advice where appropriate; and
- e) report any illegal or unethical behavior to the CEO and the Board of Directors;
- f) obey laws that prohibit bribery and corrupt practices in dealing with foreign governments, in particular, the provisions of the Canadian Corruption of Foreign Public Officials Act (the "CFPOA"): team members may not give, offer or agree to give a benefit of any kind to a foreign public official or to any person for the benefit of a foreign public official (a) as consideration for an act by the official in connection with the official's duties, or (b) to induce the official to use their position to influence any acts of the foreign state or public

international organization except in those limited circumstances set out in the CFPOA **AND** only with the permission of the Board of Directors; and

- g) obey all securities laws including those dealing with insider trading and will adhere to the Company's Insider Trading and Blackout Policy.

If we do any business outside of Canada, we have a special responsibility to know and obey the laws and regulations of foreign countries. Customs vary throughout the world, but we must diligently uphold the integrity of the Company in other nations.

3.5 We Keep Accurate and Complete Records

We are a public company and therefore team members must provide prompt, accurate answers to inquiries related to the Company's public disclosure requirements.

We will maintain the integrity of records and financial reporting because it is critical to our on-going success. All assets, liabilities and transactions must be accurately and completely reported in the books and supported by necessary documentation in accordance with generally accepted accounting principles, including international financial reporting standards. No one will ever consider concealing, or falsifying any records or manipulating or destroying records for the purpose of impeding or obstructing any investigation undertaken by the Company or a governmental body. No team member would ever act in a way that might fraudulently influence or mislead anyone engaged in the performance of an audit of the Company's financial statements.

We understand that the integrity of records is critical and we will develop a records management policy and records retention policy that meets ISO 15489 standards for records.

3.6 We Avoid Conflicts of Interest

Team members must act honestly, in good faith, and in the best interests of the Company. Team members should avoid situations where their personal interest could conflict with, or appear to conflict with, the interests of the Company and its shareholders. Questions or reports regarding any conflict of interest or potential conflict of interest should be directed to the Chief Executive Officer.

The following are examples of conflicts that may arise in the course of carrying out the Company's business:

- a) **Outside Business Interests.** Team members are free to take on employment and other activities outside of their work responsibilities with the Company. However, in doing so, team members must ensure that any "outside" activities do not present a real or perceived conflict with the interests of the Company or with their duties as team members.
- b) **Outside Directorships.** Team members are free to take on directorships, however, team

members must be aware of any potential for conflicts with the interests of the Company.

- c) **Financial Interests in Suppliers, Contractors or Competitors.** Any proposed affiliation between team members and any entity that has a relationship with the Company is subject to review by the Board of Directors to determine whether or not there is a conflict of interest.
- d) **Outside Personal Loan or Guarantee from the Company.** Team members should not accept, whether directly or indirectly, any loan or guarantee of obligations from the Company or its shareholders for personal benefit.

3.7 We Protect and Use Corporate Assets Appropriately

Proper use of Company property is everyone's responsibility. All team members have an obligation to protect the Company's assets, including opportunity, information, and Mydecine's name and good will, and ensure their efficient and careful use. Team members cannot appropriate a corporate opportunity or corporate property, arising out of their relationship with the Company, for their own personal benefit.

Theft, carelessness and waste have a direct impact on the Company's profitability. Report any suspected incident of fraud or theft to any member of management, including the Chief Executive Officer.

E-mail systems and internet services are provided to assist team members in the performance of their duties. Incidental or occasional personal use is permitted, but never for personal gain or improper purpose. As email may not be entirely secure, team members must exercise caution and etiquette when sending email correspondence. Team members' messages (including voice mail), computer information and communication records are considered property of the Company and team members should not have any expectation of privacy. Unless prohibited by law, the Company reserves the right to access and disclose this information as necessary for business purposes.

Team members should never borrow or remove Company property without management's prior written authorization.

Business documents and records (voice, paper and electronic) will be retained in accordance with the law and the Company's records management policy as may be adopted or amended from time to time.

3.8 We Avoid Illegal and Questionable Gifts

Team members or their families, will not solicit or accept any type of kickbacks, rebates or "under-the-table" payments in exchange for any decision, act or omission by any team members in the course of carrying out their functions.

Similarly, team members should not try to influence the decisions of a supplier or customer

by giving gifts. Anyone receiving any such gift, loan, reward or benefit must report the same to the Ethics Officer. The giving and receiving of modest gifts or entertainment as a part of normal business courtesy and hospitality is permitted. However, the use of expense accounts to deviate from any policy described herein is strictly forbidden.

3.9 We Maintain the Confidentiality of Information

Confidential information is any information that is not known to the general public and includes business research, market plans, strategic objectives, unpublished financial information, customer, supplier and personnel lists and all intellectual property, including trade secrets, software, trademarks, copyrights and patents. Confidential information may not be given or released without proper authority and appropriate protection to anyone not employed by the Company or to team members who have no need for such information.

Team members must protect the confidentiality of information concerning the Company and its business activities as well as that of companies having business dealings with the Company. Employees who leave the Company have an ongoing obligation to keep such information confidential.

Care must be taken not to discuss confidential, personal or sensitive information in social or public meetings. Team members are expected to keep confidential personal details with respect to their employment with the Company such as salaries, stock option grants and other such information. Outside speeches or articles for outside publication containing information relating to the Company's affairs or activities require approval in advance in accordance with our Corporate Disclosure Policy.

Team members are prohibited from trading or encouraging others to trade in the securities of the Company where the person trading is in possession of material non-public information.

4.0 COMMUNICATE AND ENFORCE THIS CODE

4.1 Communication of this Code

You will be asked to acknowledge receipt and acceptance of this Code in writing and will receive a copy of this Code.

4.2 Reporting Code Violations

Anyone who becomes aware of any existing or potential violation of this Code should promptly notify his or her supervisor. If reporting to your supervisor is not practical or if this does not resolve the issue, team members may take their concern to one of the reporting contacts noted in Item 6.0.

All reports made under this Code will be treated in confidence and involve only those individuals necessary to conduct an investigation into the matter.

Retaliation in any form against an individual who reports a violation of this Code or of law

in good faith, or who assists in the investigation of a reported violation, is itself a serious violation of this Code. Acts of retaliation should be reported immediately to your supervisor or management, and will be disciplined appropriately.

The Ethics Officer and the Audit Committee will retain, on a confidential basis, any complaints received for a period of six years.

5.0 DO ASK QUESTIONS

This Code cannot, and is not intended to, address all of the situations we may encounter. There will be occasions where one is confronted by circumstances not covered by policy or procedure and where one must make a judgment as to the appropriate course of action.

If you have any questions about how this Code should be followed in a particular case, please contact your supervisor or the Company Ethics Officer.

6.0 CONTACTS

1 Your supervisor

2 Company Ethics Officer

**MYDECINE INNOVATIONS GROUP INC.
CODE OF ETHICS AND BUSINESS CONDUCT**

COMPLIANCE CERTIFICATE

I have read and understand the Mydecine Code of Ethics and Business Conduct (the "*Code*"). I will adhere in all respects to the ethical standards described in this Code. I further confirm my understanding that any violation of this Code will subject me to appropriate disciplinary action, which may include reprimand, suspension, or discharge. Execution of this certificate does not constitute a waiver of any other rights I may have by law or contract.

Date: _____

By: _____

(Signature)

Name: _____

(please print)

Job Title: _____

2. Insider Trading and Blackout Policy



MYDECINE INNOVATIONS GROUP INC.

Insider Trading and Blackout Policy

1.0 INTRODUCTION

The board of directors of Mydecine Innovations Group Inc. (“**Mydecine**”, the “**Company**”, “**our**” or “**we**”) understand the importance of equal access to information about publicly-traded companies. Open and transparent reporting of insider transactions provides the investing community with the information they need to make informed decisions. To help the employees, officers, and directors of the Company understand their obligations under application Insider Trading rules and regulations, the Company has developed this Insider Trading and Blackout Policy (the “**Policy**”). For the purposes of this Policy Mydecine includes any subsidiaries of the Company from time to time.

2.0 PURPOSE OF THE POLICY

Canadian securities laws prohibit **insider trading** and impose restrictions on the trading of shares or other securities issued by the Company while one is in possession of material undisclosed information and also prohibits a person from sharing that information with anyone else until it has been publicly disclosed.

As a public company, Mydecine has developed internal guidelines to control transactions involving its securities by all of our directors, officers and employees to ensure that they are aware of, and comply with, their legal obligations and Mydecine’s policy with respect to “insider trading” and “tipping”.

This Policy is also intended to ensure that all representatives of the Company act, and are perceived to act, in accordance with applicable laws and the highest standards of ethical and professional behaviour.

This Policy covers all directors, officers and employees, as well as individuals who have a *special relationship* with the Company, as such term is defined in Section 3 of the *Securities Act* (British Columbia) and outlined in Section 5.0 herein.

3.0 MATERIAL INFORMATION

Material information, as defined in applicable legislation and regulations, is information that could be reasonably expected to have an impact on the price of the Company’s securities or that would have an effect on investment decisions by a reasonable investor.

4.0 INSIDERS

4.1 A person is an insider of Mydecine if that person is:

- (a) the CEO, CFO or COO of the reporting issuer, of a significant shareholder of the reporting issuer or of a major subsidiary of the reporting issuer;
- (b) a director of the reporting issuer, of a significant shareholder of the reporting issuer or of a major subsidiary of the reporting issuer;
- (c) a person or company responsible for a principal business unit, division or function of the reporting issuer;
- (d) a significant shareholder of the reporting issuer;
- (e) a significant shareholder based on post-conversion beneficial ownership of the reporting issuer's securities and the CEO, CFO, COO and every director of the significant shareholder based on post-conversion beneficial ownership;
- (f) a management company that provides significant management or administrative services to the reporting issuer or a major subsidiary of the reporting issuer, every director of the management company, every CEO, CFO and COO of the management company, and every significant shareholder of the management company;
- (g) an individual performing functions similar to the functions performed by any of the insiders described in paragraphs (a) to (f);
- (h) the reporting issuer itself, if it has purchased, redeemed or otherwise acquired a security of its own issue, for so long as it continues to hold that security; or
- (i) any other insider that (i) in the ordinary course receives or has access to information as to material facts or material changes concerning the reporting issuer before the material facts or material changes are generally disclosed; and (ii) directly or indirectly exercises, or has the ability to exercise, significant power or influence over the business, operations, capital or development of the reporting issue.

4.2 A "significant shareholder" means a person or company that has beneficial ownership of, or control or direction over, whether direct or indirect, or a combination of beneficial ownership of, and control or direction over, whether direct or indirect, securities of an issuer carrying more than 10 per cent of the voting rights attached to all the issuer's outstanding voting securities, excluding, for the purpose of the calculation of the percentage held, any securities held by the person or company as underwriter in the course of a distribution

5.0 SPECIAL RELATIONSHIPS

A person is in a special relationship with Mydecine if the person is:

- (a) an insider of Mydecine;
- (b) a director, officer or employee of Mydecine or its subsidiaries;
- (c) a person or company that is or proposes to engage in any business or professional activity with or on behalf of Mydecine; or
- (d) a person or company that learns of a material fact or material change from another person or company and knows or ought reasonably to have known that the other person or company is in a special relationship with Mydecine.

6.0 CONFIDENTIALITY

No one in a special relationship with the Company may inform or “tip” anyone else of any undisclosed material information, the exception being that a person may provide such information as may be necessary in the ordinary course of business. If you are uncertain as to whether or not you should disclose information, you should consult with the CEO or the CFO, who are designated as “Trading Officers” for the purpose of this Policy.

Any outside parties who are aware or may become aware of undisclosed material information concerning the Company may be required to sign a confidentiality and non-disclosure agreement and will be advised that they must not share this information with anyone else, other than in the necessary course of business and that they may not trade in the Company's securities until the information is publicly disclosed.

7.0 RESTRICTIONS ON TRADING

Persons in a special relationship with the Company and who are in possession of material information are prohibited from trading in the securities of the Company until the next full business day after the day on which such material information is disseminated in accordance with Mydecine’s Disclosure Policy.

Furthermore such persons may not pass on this information to others until after the material information has been publicly disclosed.

These restrictions apply to the person with the special relationship as well as members of his or her household.

8.0 BLACKOUT PERIODS

In general, persons or companies in a special relationship with Mydecine may not trade their securities in Mydecine during the period commencing from the period after which they receive financial information after the end of an interim period or year-end and the first business day following the filing of the interim or year-end report on SEDAR.

Note that Mydecine must release its interim financial statements no later than 60 days following the end of each three month period and must release its audited annual financial statements not later than 120 days following the end of its financial year end.

At the present time, our fiscal periods are as follows:

Period
Q1 – 3 months ended March 31
Q2 – 6 months ended June 30
Q3 – 9 months ended September 30
YE – 12 months ended December 31

The corporate secretary will remind those in a special relationship when Blackout Periods begin and end.

9.0 RESPONSIBILITY

9.1 Complying with Securities Laws

Each individual is responsible for obeying and complying with applicable insider trading regulations and for adhering to securities laws. This Policy is not intended to, nor does it supersede or override such statutes and regulations.

9.2 Filing of Insider Reports on SEDI

Each individual is responsible for filing their own reports on SEDI, the System for Electronic Disclosure by Insiders whether by filing themselves or by having an agent file their insider reports. Insiders are reminded to file their Insider reports in accordance with applicable rules to maintain the integrity of the Company's disclosure regime.

9.3 Consequences

Under Canadian securities laws, an individual who engages in insider trading may be fined or imprisoned, and may face civil liability.

Late filing of insider reports will result in fines levied by the securities commission.

Failure to comply with this policy or the procedures set out herein may result in Mydecine taking appropriate disciplinary action, which may include termination of employment or an independent contractor arrangement for cause.

10.0 COMMUNICATION AND ENFORCEMENT OF THE POLICY

A copy of the Policy will be distributed to all directors, officers, employees, and consultants and these persons will be asked to acknowledge the Policy in writing. Failure to adhere to this Policy may represent a violation of certain securities laws. If the Company discovers that an employee has violated such security laws, it may refer the matter to appropriate regulatory authorities.

11.0 REVIEW OF POLICY

This Policy will be reviewed from time to time and at least on an annual basis and will be updated whenever insider trading regulations are amended.

12.0 QUERIES

If you have any questions about how this Policy should be followed in a particular case, please contact the Corporate Secretary or one of the designated Trading Officers, that is, the CEO or CFO.

13.0 ADOPTION OF POLICY

This policy was adopted by the board of directors of the Company effective May 15, 2017.

-signature page follows-

**MYDECINE INNOVATIONS GROUP INC.
INSIDER TRADING AND BLACKOUT POLICY**

ACKNOWLEDGEMENT

The undersigned has read, understands and agrees to abide by the terms of the above Mydecine Innovations Group Inc. Insider Trading and Blackout Policy and acknowledges receipt of a signed copy.

Date: _____

By: _____

(Signature)

Name: _____

(please print)

Title: _____

3. Disclosure Policy



MYDECINE INNOVATIONS GROUP INC.

Disclosure Policy

1.0 INTRODUCTION

The board of directors of Mydecine Innovations Group Inc. (the “**Company**”, “**our**” or “**we**”) recognizes the importance of clear, concise, and timely disclosure of material information and our ongoing obligation to maintain the corporate website as a communications tool for our stakeholders. We have adopted this Corporate Disclosure Policy (the “**Policy**”) to assist employees, officers and directors to understand the Company’s continuous disclosure obligations pertaining to corporate communications.

News releases are confidential internal documents that contain insider information and must be treated as such. If major news is in the works, the CEO should consider whether invoke a trading blackout for insiders is appropriate.

2.0 PURPOSE OF THE POLICY

The purpose of this policy is to ensure that communications with the investing public are:

- a) Timely, accurate and factual;
- b) Broadly disseminated in accordance with all applicable legal and regulatory requirements.

This Policy covers all employees, contractors, officers and directors of the Company (the “**Team**”). It applies to all written communications including financial reports, news releases, newsletters, information on the corporate website, social media posts, letters, or presentations. It also extends to verbal communications by any spokesperson for the Company.

This Policy will serve to remind our employees, contractors, officers, and directors of our timely disclosure obligations under CSE policy; of our continuous disclosure obligations as they relate to corporate communications under NI-51-102 *Continuous Disclosure Obligations*; of the process for preparing, disseminating, and recording news releases issued by the Company; and the process for developing, maintaining, and updating the corporate website.

3.0 MATERIAL INFORMATION

All material information will be disclosed via news releases to be widely disseminated using an approved newswire service. Material information, as defined in applicable legislation and regulations, is information that could be reasonably expected to have an impact on the price of the Company's securities or that would have an effect on investment decisions by a reasonable investor.

Unfavourable material information will be released as promptly and completely as favourable material information.

4.0 DISCLOSURE REVIEW

All material information must be brought to the attention of the CEO and CFO who will determine if a news release is required. If they deem a news release to be necessary they will authorize its preparation and will be responsible for reviewing its contents before it is circulated to the remaining members of the executive team and to the board of directors.

The Corporate Secretary is the officer responsible for ensuring that all rules, regulations, and policies are followed with respect to corporate communications. If the Company engages a corporate communications or investor relations professional, the Corporate Secretary must be apprised of all corporate information to be distributed prior to its distribution.

5.0 DESIGNATED PERSONS

5.1 Spokespersons

The Company spokespersons are responsible for communications with the investment community, media and the general public. The CEO, CFO, and Vice Presidents are the only official spokespersons for the Company. Individuals holding these titles may, from time to time designate others within the Company to speak on behalf of the Company as back-ups or to respond to specific inquiries.

5.2 Person Responsible for Dissemination

Under this Policy, the Corporate Secretary is designated as the person responsible for disseminating news releases; this responsibility can only be exercised under authority from the board of directors. The Corporate Secretary may appoint a responsible assistant or alternate person to disseminate news releases.

5.3 Corporate Website Updates

Under this Policy, the Corporate Secretary is designated as the person responsible for updating disclosure on the corporate website. The Corporate Secretary may appoint a responsible assistant or alternate person to perform this function.

6.0 CONFIDENTIALITY

Access to undisclosed material information should be limited to those who need to know the information. If an employee is privy to confidential information, he or she is prohibited from communicating this information, unless it is necessary to do so in the course of business.

Any outside parties who are aware or may become aware of undisclosed material information concerning the Company may be required to sign a confidentiality and non-disclosure agreement and will be advised that they must not share this information with anyone else, other than in the necessary course of business and that they may not trade in the Company's securities until the information is publicly disclosed.

7.0 NEWS RELEASES

Draft news releases should be marked as a draft and distributed to the board and management for their information, review, and comments requesting their input as appropriate. All board members must be aware of the news release before it is disseminated; the board is responsible for the content of all news releases.

The Company will adhere to CSE policy. If a news release contains material information that may require a halt, a copy of the release, if deemed appropriate, will be sent to the CSE and IIROC before release to decide if trading should be halted.

Once board and CSE/IIROC approval, if required, is received, the Company will provide a copy to the Corporate Secretary who will mark it as FINAL and issue the release and post it on the Company's website.

If there is any uncertainty, the Company will seek legal or other expert advice. Once all uncertainties are dealt with the news release is marked FINAL.

8.0 SOCIAL MEDIA

8.1 Mitigating Risk

It is important that we mitigate the securities law risks presented by the use of social media. These are our rules:

- 8.1.1 Team Members are responsible for knowing, understanding and following Mydecine's Social Media practices set out in this policy, including the Social Media Best Practices set out under Item 8.2.

- 8.1.2 All social media posts have the potential to affect the Company, therefore Team Members must not post about the Company on their personal Social Media accounts.
- 8.1.3 The social media accounts belong to the Company and must be corporate sites. No personal sites are permitted. Only the Corporate Secretary may create new social media accounts.
- 8.1.4 The passwords and email addresses used on the Company's social media accounts are created and maintained only by the Corporate Secretary or a person authorized by the Corporate Secretary.
- 8.1.5 Only designated spokespersons may post on social media.
- 8.1.6 Social media posts will be restricted to previously disseminated news.
- 8.1.7 Management will designate a corporate communications person to monitor and report on social media accounts, including third party postings.
- 8.1.8 Any reposting of third parties' social media posts without the consent of management is a violation of this policy and could result in disciplinary action including dismissal for cause.

8.2 Social Media Best Practices

8.2.1 Delay social media communications

Supplemental communications channels (i.e., social media) cannot be used until the information has been “generally disclosed” using traditional means. This means that at least 30 minutes must elapse before any social media, blog or newsletter posting of information. News releases and other disclosure will provide information on what social media channels the Company is using. *Management may choose to increase the length of the delay depending on a number of factors including the nature and complexity of the information and the nature of the market for the Company's securities.*

8.2.2 Include all material information disclosed

Disclosures made by traditional means should be included in their entirety when communicated using social media. However, if this is not practical, include a link to the full disclosure as part of the social media disclosure. *Care must be taken to ensure that excerpts are not misleading when read on their own.*

8.2.3 Present information in a consistent manner

Investor relations information disclosed via social media must be presented in the same manner as it is through traditional means. Do not divide Company communication into a series of shorter communications if the result obscures or

buries unfavourable information or alters the import of the information. Include the link to the full disclosure.

8.2.4 Treat favourable and unfavourable information consistently

Be consistent when communicating via social media. For example, if company practice is to supplement earnings pre-release news release announcements with social media communications, the practice should be followed even when the earnings are disappointing.

8.2.5 Do not be overly promotional

Investor relations information disclosed via social media is part of our disclosure record. Social media is not to be used as a promotional tool. For example, do not prominently featuring our trading symbol in an effort to promote stock sales.

8.2.6 Keep a record of social media disclosures

The social media spokesperson must keep a thorough and well organized record of social media disclosure and must make the social media disclosure record available to management and/or directors immediately upon their request. ***Our officers and directors are accountable for all disclosure, including social media.***

8.2.7 Do not use social media as an alternative to prescribed requirements

Social media does not replace the requirement for us to issue news releases or material change reports and cannot and must not be used as a substitute for these.

8.2.8 Consider requirements applicable to specific statements within social media communications

The content of social media communications must comply with any applicable requirements relating to specific types of statements, such as forward-looking information (FLI) and financial disclosure. Social media communications should reference any required disclosure regarding FLI, material risk factors and assumptions.

8.2.9 Avoid prohibited disclosures during a prospectus offering

Do not use social media to distribute a preliminary prospectus or prospectus notice or to distribute any materials related to a prospectus offering.

8.2.10 Do not solicit proxies before a management information circular has been filed

Do not try to respond to any comments via social media or other means prior to an information circular being filed. Be particularly aware of this if a dissident shareholder is making inflammatory public statements and soliciting proxies in accordance with applicable law.

9.0 MATERIAL CHANGE REPORT

The Corporate Secretary will prepare and file a material change report on Form 51-102F3 within 10 days of the news release being disseminated. The CEO will sign off on the MCR prior to its filing.

10.0 COMPANY WEBSITE

The CEO, CFO and Corporate Secretary will monitor all information placed on the Company's website to ensure that it is accurate, complete and up to date. The Company website is a continuous disclosure document and must be updated in a timely manner whenever material information is released, including interim and annual reports, and news releases. Any disclosure of material information on its website will be coordinated with a news release.

The Company website will include forward-looking disclosure.

11.0 RETENTION OF RECORDS

11.1 News Releases

Only one final version of the release must survive the editing process. All drafts, convenience copies, email conversations discussing content, etc. must be deleted from all computers, tablets, smart phones immediately after news release is approved for dissemination. The official version will be filed in the corporate records.

Save final circulated version to the Company's electronic document management system.

11.2 Company Website

The Company website content files must be retained in the corporate records.

11.3 Social Media Content

The Social Media content compiled under Item 8.2.6 will be sent to the Corporate Secretary at the end of each quarter to be added to the Company's document management system.

12.0 COMMUNICATION AND ENFORCEMENT OF THE POLICY

A copy of the Policy will be distributed to all directors, officers, employees, contractors and consultants involved in continuous disclosure and these persons will be asked to acknowledge the Policy in writing. Failure to adhere to this Policy may represent a violation of certain securities laws and may be grounds for dismissal with cause. Additionally, if the Company discovers that an employee has violated such security laws, it may refer the matter to appropriate regulatory authorities.

13.0 REVIEW OF POLICY

This Policy will be reviewed from time to time and at least on an annual basis and will be updated whenever continuous disclosure regulations are amended.

14.0 QUERIES

If you have any questions about how this Policy should be followed in a particular case, please contact the Corporate Secretary.

15.0 ADOPTION OF POLICY

This policy was adopted by the board of directors of the Company on May 15, 2017.

-signature page follows-

MYDECINE INNOVATIONS GROUP INC.

DISCLOSURE POLICY

ACKNOWLEDGEMENT

The undersigned has read, understands and agrees to abide by the terms of the above Mydecine Innovations Group Inc. Corporate Disclosure Policy and acknowledges receipt of a signed copy.

Date: _____

By: _____

(Signature)

Name: _____

(please print)

Title: _____